As filed with the Securities and Exchange Commission on February 28, 2019
Registration No. 333-
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
 
TOCAGEN INC.
(Exact name of registrant as specified in its charter)

			
 	 	 	
Delaware	 	26-1243872	
(State or other jurisdiction of
incorporation or organization)	 	(I.R.S. Employer
Identification No.)	
 	 	
4242 Campus Point Court, Suite 500
San Diego, California	 	92121	
(Address of Principal Executive Offices)	 	(Zip Code)	
 
2017 Equity Incentive Plan
2017 Employee Stock Purchase Plan
(Full titles of the plans)
Martin J. Duvall
Chief Executive Officer
Tocagen Inc.
4242 Campus Point Court, Suite 500
San Diego, California 92121
(858) 412-8400
(Name, address, and telephone number, including area code, of agent for service)
 
Copies to:

Karen E. Anderson, Esq.
Wade W. Andrews, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
Tel: (858) 550-6000	 	Mark Foletta
Executive Vice President and Chief Financial Officer
Tocagen Inc.
4242 Campus Point Court, Suite 500
San Diego, California 92121
(858) 412-8400	
 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐  	 	Accelerated filer	☒	
Non-accelerated filer	☐	 	Smaller reporting company	☒	
 	 	 	Emerging growth company	☒	
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

 
  
 CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount
to be
Registered (1)	Proposed Maximum
Offering Price
Per Share (2)	Proposed Maximum
Aggregate
Offering Price (2)	Amount of
Registration Fee	
2017 Equity Incentive Plan
Common Stock, $0.001 par value per share	1,095,006 (3)	$11.29	$12,362,617.74	$1,498.35	
2017 Employee Stock Purchase Plan
Common Stock, $0.001 par value per share	230,001 (4)	$11.29	$2,596,711.29	$314.73	
Total	1,325,007	 	$14,959,329.03	$1,813.08	
____________________________________________________________________________________________________

(1)	Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “ Securities Act ” ), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional shares of the Registrant ’ s Common Stock ( “ Common Stock ” ) that become issuable under the plans by reason of any stock dividend, stock split, recapitalization or other similar transaction.	
(2)	This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on February 27 , 2019, as reported on the Nasdaq Global Select Market.	
(3)	Represents (i) 920,006 shares of Common Stock that were automatically added to the shares authorized for issuance under the Tocagen Inc. 2017 Equity Incentive Plan, as amended (the “ 2017 Plan ” ), on January 1, 2019 pursuant to an “ evergreen ” provision contained in the 2017 Plan. Pursuant to such provision, on January 1 of each year through January 1, 2027, the number of shares authorized for issuance under the 2017 Plan is automatically increased by: (a) a number equal to 4% of the total number of shares of the Registrant ’ s capital stock outstanding on December 31 of the preceding calendar year; or (b) a number of shares of Common Stock that may be determined by the Registrant ’ s Board of Directors that is less than the preceding clause (a) and (ii) 175,000 shares of Common Stock added to the 2017 Plan pursuant to an amendment approved by the Registrant’s Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules (“Rule 5635(c)(4)”) and to be used exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Registrant (or following a bona fide period of non-employment with the Registrant), as an inducement material to the individuals’ entering into employment with the Registrant.	
(4)	Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the Tocagen Inc. 2017 Employee Stock Purchase Plan (the “ 2017 ESPP ” ), on January 1, 2019 pursuant to an “ evergreen ” provision contained in the 2017 ESPP. Pursuant to such provision, on January 1 of each year through January 1, 2027, the number of shares authorized for issuance under the 2017 ESPP is automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of the Registrant ’ s capital stock outstanding on December 31 of the preceding calendar year; (b) 300,000 shares; or (c) a number of shares of Common Stock that may be determined by the Registrant ’ s Board of Directors that is less than (a) and (b).	

 

 
 
 REGISTRATION OF ADDITIONAL SECURITIES
175,000 shares of the additional shares of Common Stock available for issuance under the 2017 Plan being registered on this Registration Statement are to be used exclusively for the grant of awards (“Inducement Awards”) to individuals who were not previously employees or non-employee directors of the Registrant (or following a bona fide period of non-employment with the Registrant), as an inducement material to the individuals’ entering into employment with the Registrant within the meaning of Rule 5635(c)(4). The 2017 Plan was amended by the Compensation Committee of the Board of Directors of the Registrant to provide for Inducement Awards without stockholder approval pursuant to Rule 5635(c)(4).
 
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2017 Plan and 2017 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on April 13, 2017 (File No. 333-217300) and March 9, 2018 (File No. 333-223558). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.
Item 8. Exhibits.

Exhibit
Number	 	Description	
 	 	 	
4.1	 	Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on April 19, 2017).	
 	 	 	
4.2	 	Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K filed on April 19, 2017).  	
 	 	 	
4.3	 	Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-216574), as amended, originally filed on March 9, 2017).	
 	 	
5.1	 	Opinion of Cooley LLP.	
 	 	
23.1	 	Consent of Independent Registered Public Accounting Firm.	
 	 	 	
23.2	 	Consent of Cooley LLP. Reference is made to Exhibit 5.1.	
 	 	
24.1	 	Power of Attorney. Reference is made to the signature page hereto.	
 	 	
99.1	 	Tocagen Inc. 2017 Equity Incentive Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 of the Registrant’s Annual Report on Form 10-K filed on February 27, 2019).	
 	 	 	
99.2	 	Tocagen Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-216574), as amended, originally filed on March 9, 2017).	

 

SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 28, 2019.

Tocagen Inc.	
 	 	
By:	 	/s/ Martin J. Duvall	
 	 	Martin J. Duvall	
 	 	Chief Executive Officer	
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Martin J. Duvall and Mark Foletta, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	 	Title	 	Date	
 	 	 	 	 	
/s/ Martin J. Duvall	 	Chief Executive Officer and
Member of the Board of Directors
(Principal Executive Officer)  	 	February 28, 2019	
Martin J. Duvall	 		 	 	
 	 	 	 	 	
/s/ Mark Foletta	 	Chief Financial Officer
(Principal Financial and Accounting Officer)
 	 	February 28, 2019	
Mark Foletta	 		 	 	
 	 	 	 	 	
/s/ Faheem Hasnain	 	Chairman of the Board of Directors	 	February 28, 2019	
Faheem Hasnain	 	 	 	 	
 	 	 	 	 	
/s/ Franklin M. Berger	 	Member of the Board of Directors	 	February 28, 2019	
Franklin M. Berger	 	 	 	 	
 	 	 	 	 	
/s/ Thomas E. Darcy	 	Member of the Board of Directors	 	February 28, 2019	
Thomas E. Darcy	 	 	 	 	
 	 	 	 	 	
/s/ Harry E. Gruber, M.D.	 	Member of the Board of Directors	 	February 28, 2019	
Harry E. Gruber, M.D.	 	 	 	 	
 	 	 	 	 	
/s/ David Parkinson, M.D.	 	Member of the Board of Directors	 	February 28, 2019	
David Parkinson, M.D.	 	 	 	 	
 	 	 	 	 	
/s/ Paul Schimmel, Ph.D.	 	Member of the Board of Directors	 	February 28, 2019	
Paul Schimmel, Ph.D.	 	 	 	 	

		
	Exhibit 5.1	

Karen E. Anderson
+1 858 550 6088
kanderson@cooley.com

 

 

 

 
February 28, 2019
Tocagen Inc.
4242 Campus Point Court, Suite 500
San Diego, CA 92121
 
Ladies and Gentlemen:
We have acted as counsel to Tocagen Inc., a Delaware corporation (the “ Company ”), and you have requested our opinion in connection with the filing by the Company of a registration statement on Form S‑8 (the “ Registration Statement ”) with the Securities and Exchange Commission, covering the offering of up to an aggregate of 1,325,007 shares of the Company’s Common Stock, $0.001 par value (the “ Shares ”), including (i) 1,095,006 shares reserved for issuance pursuant to the Company’s 2017 Equity Incentive Plan, as amended (the “ 2017 Plan ” ), and (ii) 230,001 shares reserved for issuance pursuant to the Company’s 2017 Employee Stock Purchase Plan (the “ 2017 ESPP ”).
In connection with this opinion, we have examined and relied upon the Registration Statement and the related prospectuses included therein, the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect, the 2017 Plan and the 2017 ESPP and the originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as we deem necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies thereof .  As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware.  We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the 2017 Plan and the 2017 ESPP, respectively, and the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to Shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

 Cooley LLP   4401 Eastgate Mall   San Diego, CA   92121
t: (858) 550-6000  f: (858) 550-6420  cooley.com

	

Tocagen

Page 2	
 
We consent to the filing of this opinion as an exhibit to the Registration Statement.
 
Sincerely,
Cooley LLP
By:   /s/ Karen E. Anderson
Karen E. Anderson

Cooley LLP   4401 Eastgate Mall   San Diego, CA   92121
t: (858) 550-6000  f: (858) 550-6420  cooley.com

Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2017 Equity Incentive Plan, as amended, and the 2017 Employee Stock Purchase Plan of Tocagen Inc. of our report dated February 27, 2019, with respect to the financial statements of Tocagen Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2018, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP
San Diego, California
February 28, 2019